Pulmonary Mycobacterium szulgai infection and treatment in a patient receiving anti-tumor necrosis factor therapy
- 1 July 2007
- journal article
- case report
- Published by Springer Nature in Nature Clinical Practice Rheumatology
- Vol. 3 (7) , 414-419
- https://doi.org/10.1038/ncprheum0538
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Development of sarcoidosis during etanercept therapyArthritis Care & Research, 2006
- Infliximab for Rheumatoid Arthritis in a Patient with TuberculosisNew England Journal of Medicine, 2006
- Tumor‐Necrosis‐Factor Blockers: Differential Effects on Mycobacterial ImmunityThe Journal of Infectious Diseases, 2006
- Mycobacterium abscessus infection after use of tumor necrosis factor α inhibitor therapy: case report and review of infectious complications associated with tumor necrosis factor α inhibitor useDiagnostic Microbiology and Infectious Disease, 2005
- Reconsidering Adjuvant Immunotherapy for TuberculosisClinical Infectious Diseases, 2005
- Paradoxical Response to Antituberculous Therapy in Infliximab-Treated Patients with Disseminated TuberculosisClinical Infectious Diseases, 2005
- Pseudoepidemic Due to a Unique Strain of Mycobacterium szulgai : Genotypic, Phenotypic, and Epidemiological AnalysisJournal of Clinical Microbiology, 2002
- Experience with etanercept in an academic medical center: Are infection rates increased?Arthritis & Rheumatism, 2002
- Management of opportunist mycobacterial infections: Joint Tuberculosis Committee guidelines 1999Thorax, 2000
- Quantitative PCR of mycobacterial and propionibacterial DNA in lymph nodes of Japanese patients with sarcoidosisPublished by Elsevier ,1999